FLT3 and acute myeloid leukemia: A number of reviews report a prevalence of around 25% for FLT3‐ITD mutations in patients with AML and 5%–10% for FLT3‐TKD [1, 2, 3], but these do not reflect an objective summary assessment of the prevalence of FLT3 mutations.